227
AMD Future Perspectives: New promising drugs
With Subfoveal Choroidal Neovascularization Associated With
Age-Related Macular Degeneration.
/
show/NCT00090532?term=AG-013958&rank=1 Accessed in
29 March 2010.
29. Phase I Study of an Ocular Sirolimus (Rapamycin) Formulation
in Combination With Lucentis® in Patients With Age-Related
Macular Degeneration (EMERALD)
ct2/show/NCT00766337?term=macusight&rank=1 Accessed in
29 March 2010.
30. Zahn G, Vossmeyer D, Stragies R, Wills M, Wong CG, Löffler
KU, Adamis AP, Knolle J. Preclinical evaluation of the novel
small-molecule integrin alpha5beta1 inhibitor JSM6427 in
monkey and rabbit models of choroidal neovascularization. Arch
Ophthalmol. 2009 Oct;127(10):1329-35.
31. Citation
/
32. A phase I Ascending and Parallel Group Trial to Establish the
Safety, Tolerability and Pharmacokinetics Profile of Volociximab
(Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascu-
lar Age- Related Macular Degeneration
/
ct2/show/NCT00782093?term=volociximab&rank=9 Accessed
25 March 2010.
33. Study Evaluating the Safety and Response of Fosbretabulin in
Asian Patients With Polypoidal Choroidal Vasculopathy(PCV).
&rank=1. Accessed 26 March 2010.
34. Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, Hu RS, Tsao
PS, Johnson FL, Cooke JP. Nicotine stimulates angiogenesis and
promotes tumor growth and atherosclerosis. Nat Med. 2001
Jul;7(7):833-9.
35. Christopher Heeschen, Michael Weis, Alexandra Aicher, Stefanie
Dimmeler, John P. Cooke A novel angiogenic pathway mediated
by non-neuronal nicotinic acetylcholine receptors J. Clin. Invest.
2002; 110(4):527.
36. Arias HR, Richards VE, Ng D, Ghafoori ME, Le V, Mousa SA.
Role of non-neuronal nicotinic acetylcholine receptors in angio-
genesis. Int J Biochem Cell Biol. 2009 Jul;41(7):1441-51. Epub
2009 Jan 29. Review.
37. Safety and Efficacy of ATG003 in Patients With Wet Age-Relat-
ed Macular Degeneration (AMD)
ct2/show/NCT00414206?term=mecamylamine+amd&rank=2
Accessed in 28 March 2010.
38. Safety and Efficacy of ATG003 in Patients With AMD Receiving
Anti-VEGF
750?term=mecamylamine+amd&rank=1 Accessed in 28 March
2010.
39. Duh EJ, Yang HS, Suzuma I, Miyagi M, Youngman E, Mori K,
et al: Pigment epithelium-derived factor suppresses ischemia-
induced retinal neovascularization and VEGFinduced migration
and growth. Invest Ophthalmol Vis Sci 2002; 43: 821–829.
40. Mori K, Gehlbach P, Ando A, McVey D, Wei L, Campochiaro
PA: Regression of ocular neovascularization in response to in-
creased expression of pigment epithelium-derived factor. Invest
Ophthalmol Vis Sci 2002; 43: 2428–2434.
41. Imai D, Yoneya S, Gehlbach PL, et al. Intraocular gene transfer of
pigment epithelium– derived factor rescues photoreceptors from
light-induced cell death. J Cell Physiol 2005;202: 570–578.
42. Campochiaro PA, Nguyen QD, Shah SM, Klein ML, Holz E,
Frank RN, et al: Adenoviral vector-delivered pigment epitheli-
um-derived factor for neovascular age-related macular degenera-
tion: results of a phase I clinical trial. Hum Gene Ther 2006; 17:
167–176.
43. Rasmussen H, Chu KW, Campochairo P, Gehlbach PL, Haller
JA, Handa JT, et al: An open-label, phase I, single administra-
tion, dose-escalation study of ADGVPEDF.11D (ADPEDF)
in neovascular age-related macular degeneration (AMD). Hum
Gene Ther 2001; 12: 2029–2032.
44. Clinical Trial in Age-Related Macular Degeneration” - Oral
presentation at the American Society for Gene Therapy Annual
Meeting, June 2007.
45. “All Trans-Retinoic Acid Regulation of Transgene Expression”
- Poster presented at the Association of Research for Vision in
Ophthalmology (ARVO) 2006 Annual Meeting, April 2006.
46. Voigt K, Izsvák Z, Ivics Z. Targeted gene insertion for molecular
medicine. J Mol Med. 2008 Nov;86(11):1205-19. Epub 2008
Jul 8. Review.
47. Campochiaro PA. Ocular neovascularisation and excessive vas-
cular permeability. Expert Opin Biol Ther. 2004 Sep;4(9):1395-
402. Review.
48. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H
polymorphism in age-related macular degeneration. Science.
2005;308:385-389.
49. Edwards AO, Ritter R 3rd, Abel KJ, Manning A, Panhuysen C,
Farrer LA.Complement factor H polymorphism and age-related
macular degeneration. Science. 2005;308:421-424.
50. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for
local inflammation in the formation of drusen in the aging eye.
Am J Ophthalmol. 2002 Sep;134(3):411-31.
51. Haines JL, Hauser MA, Schmidt S, et al.Complement factor H
variant increases the risk of age-related macular degeneration.
Science. 2005;308:419-421.
52. Yates JR, Sepp T, Matharu BK, et al; Genetic Factors in AMD
Study Group. Complement C3 variant and the risk of age-related
macular degeneration. N Engl J Med. 2007;357:553-561.
53.
. Accessed
in 29 March 2010.
54. Safety of Intravitreal POT-4 Therapy for Patients With Neo-
vascular Age-Related Macular Degeneration (AMD) (ASaP).
4&rank=1. Accessed in 29 March 2010.
55. Schnatbaum K, Locardi E, Scharn D, Richter U, Hawlisch H,
Knolle J, Polakowski T. Peptidomimetic C5a receptor antagonists
with hydrophobic substitutions at the C-terminus: increased re-
ceptor specificity and in vivo activity. Bioorg Med Chem Lett.
2006 Oct 1;16(19):5088-92. Epub 2006 Jul 28.
56. Citation
Ac-
cessed in 29 March 2010.
57. Complement Inhibition With Eculizumab for the Treatment of
